Winston Pharmaceuticals (WPHM) Inactive 10-K2009 FY Annual report

Filed: 5 Mar 10, 12:00am

Content analysis

Positive
Negative
Uncertain
Constraining
Legalese
Litigious
Readability	8th grade Avg

New words: abdominal, abuse, Accreditation, adalimumab, addiction, adherence, administered, advantage, afflicted, age, aging, aimed, appeal, appealed, arbitration, ASC, Asia, ASU, authoritative, Aveva, BACKGROUND, Baseline, bathe, beneficiary, billboard, biopharmaceutical, blood, bloody, bowel, branded, breakthrough, call, carcinogenic, cardiovascular, cartilage, Castle, Catalant, cation, CDOM, cited, coated, Codification, complication, concentration, conference, congestion, constant, costly, countered, Crohn, decentralized, declaratory, denial, dermatome, diagnosing, diarrhea, diclofenac, differentiating, dissatisfied, District, dying, Earlier, ECH, essential, fallen, familiarity, fasting, fed, fewer, Fine, Frameworkissued, gel, generalist, handle, healed, heightened, hepatoxicity, hiring, Hsiao, Humira, immense, IMS, inconsistent, increasingly, incumbent, inevitable, inflammation, infliximab, injunctive, interaction, interrupted, intestinal, ITT, Japan, Kingdom, Lab, Latin, leader, learned, Lidoderm, linking, LOI, Lundbeck, mesalamine, monotherapy, motion, motivate, MPA, neurological, nicknamed, ninety, nonallergic, Noncompliance, Nonqualified, Northern, nose, older, opposition, outdoor, Pacific, payroll, pecuniary, people, PFS, platform, PLX, portfolio, postherpetic, postoperative, prominent, pronounced, pronouncement, proof, rapidly, rash, recalcitrant, recover, recruiting, recurrent, regional, rely, remarked, Remicade, requisite, revert, Rim, ROX, Rubin, runny, sanofi, scale, SearchMedia, secondary, sedative, settled, SGE, shower, sicca, skill, Sleep, slight, sneezing, soft, Sorrento, source, Spain, speaker, spray, SRNE, stable, strongly, succeeded, suggested, suicide, sulfasalazine, sumatriptan, survey, surveyed, Sweden, Swedish, symposia, Syndicate, syndrome, talented, team, tendency, therapy, thinner, thought, tighten, top, tract, Trademark, trunk, TWA, undergo, unknown, Vehicle, VIE, vital, Volteren, waive, waiver, wall, WOMAC, zucapsaicin

Removed: capacity, deployment, Description, division, exceed, FIN, GTRY, interpretation, prevailing, real, role, strategy

Search this filing

Filing tables

Export all tables to Excel

Filing exhibits

WPHM similar filings

Filing view

Default size S M L
Default font Times Arial

External links

Share this filing

EXHIBIT 32.2

CERTIFICATION PURSUANT TO SECTION 906 OF
THE SARBANES-OXLEY ACT OF 2002 (18 U.S.C. SECTION 1350)

In connection with the accompanying Annual Report of Winston Pharmaceuticals, Inc. (the “Company”) on Form 10-K for the fiscal year ended December 31, 2009 (the “Report”), I, David Starr, certify, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that:

(1) The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and

(2) The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.


Dated: March 5, 2010		/s/ David Starr David Starr
		Vice President, Chief Financial Officer

This certification accompanies each Report pursuant to Section 906 of the Sarbanes-Oxley Act of 2002 and shall not, except to the extent required by the Sarbanes-Oxley Act of 2002, be deemed filed by the Company for purposes of Section 18 of the Securities Exchange Act of 1934, as amended.

A signed original of this written statement required by Section 906 has been provided to the Company and will be retained by the Company and furnished to the Securities and Exchange Commission or its staff upon request.